Production (Stage)
Tvardi Therapeutics, Inc.
TVRD
$29.09
-$3.79-11.53%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -17.59% | ||||
| Total Other Revenue | 112.36% | ||||
| Total Revenue | 20.33% | ||||
| Cost of Revenue | -98.59% | ||||
| Gross Profit | 111.00% | ||||
| SG&A Expenses | -31.98% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | -83.15% | ||||
| Operating Income | 91.25% | ||||
| Income Before Tax | 84.02% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | 84.02% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | 84.02% | ||||
| EBIT | 91.25% | ||||
| EBITDA | -- | ||||
| EPS Basic | 84.10% | ||||
| Normalized Basic EPS | 82.75% | ||||
| EPS Diluted | 84.10% | ||||
| Normalized Diluted EPS | 82.75% | ||||
| Average Basic Shares Outstanding | 0.51% | ||||
| Average Diluted Shares Outstanding | 0.51% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||